A Case of Disseminated Intra-abdominal Gastrointestinal Stromal Tumor Managed with Low Dose Imatinib.
10.4166/kjg.2015.65.6.366
- Author:
Bo Hyun JANG
1
;
Byung Wook KIM
;
Keun Joon LIM
;
Boo Gyoung KIM
;
Sung Min PARK
;
Joon Sung KIM
;
Jeong Seon JI
;
Hwang CHOI
Author Information
1. Division of Gastroenterology, Department of Internal Medicine, Incheon St. Mary's Hospital, College of Medicine, The Catholic University of Korea, Incheon, Korea. gastro@catholic.ac.kr
- Publication Type:Case Reports
- Keywords:
Gastrointestinal stromal tumors;
Imatinib
- MeSH:
Aged;
Antineoplastic Agents/adverse effects/*therapeutic use;
Exanthema/etiology;
Female;
Gastrointestinal Neoplasms/diagnosis/*drug therapy/pathology;
Gastrointestinal Stromal Tumors/diagnosis/*drug therapy/pathology;
Humans;
Imatinib Mesylate/adverse effects/*therapeutic use;
Immunohistochemistry;
Proto-Oncogene Proteins c-kit/metabolism;
Tomography, X-Ray Computed
- From:The Korean Journal of Gastroenterology
2015;65(6):366-369
- CountryRepublic of Korea
- Language:English
-
Abstract:
Gastrointestinal stromal tumor (GIST) is the most common mesenchymal tumor of the gastrointestinal tract. Imatinib mesylate is recommended as adjuvant therapy for GIST after surgical resection. However, drug-related adverse events are common. A 74-year-old female with metastatic GIST who was managed with imatinib experienced severe adverse events, including skin rashes, tremor, and alopecia, etc. The imatinib dose was reduced and the size of the metastatic GIST continued to decrease and adverse events showed significant improvement.
